SelectQuote Reports Quarterly Loss as Healthcare Services Growth Supports 2027 Outlook

SelectQuote reported fiscal fourth-quarter results Tuesday showing continued expansion in its healthcare-services operations alongside a quarterly net loss. The small-cap company, which operates insurance distribution and healthcare-service businesses, generated $321.7 million in consolidated quarterly revenue. Its shares trade under SLQT.

Revenue declined from $345.1 million in the comparable quarter a year earlier. SelectQuote recorded a net loss of $16.8 million, reversing a $12.9 million profit in the prior-year period. Adjusted EBITDA, however, improved substantially to $11.9 million from $2.7 million a year ago, indicating stronger underlying operating performance despite the reported loss.

The company's healthcare-services operation remained a major contributor during the quarter. That segment produced $193.5 million in revenue and $12.1 million in adjusted EBITDA. Membership in SelectRx, the company's medication-management and pharmacy service, reached 109,039.

SelectQuote's Senior business, which primarily connects consumers with Medicare-related insurance products, generated $72.5 million in quarterly revenue and $8 million in adjusted EBITDA. The segment reported 72,180 approved Medicare Advantage policies during the period.

The Life segment generated $47.9 million of revenue and $9.8 million in adjusted EBITDA. SelectQuote's diversified operating structure allows the company to participate in insurance distribution while increasingly generating revenue through recurring healthcare services.

For the full 2026 fiscal year, consolidated revenue reached approximately $1.6 billion, up from $1.5 billion in the previous year. Annual net income increased to $62.2 million from $47.6 million. Adjusted EBITDA declined to $109.1 million from $126.3 million, illustrating that the company's revenue and reported profitability improved even as adjusted operating earnings remained below the prior-year level.

Cash generation showed a notable improvement. SelectQuote produced $31.9 million in operating cash flow for fiscal 2026 after using $11.7 million in the previous fiscal year. The roughly $44 million year-over-year improvement was supported by the growing scale of the healthcare-services business and operating-efficiency initiatives.

Management provided fiscal 2027 guidance calling for revenue between $1.35 billion and $1.45 billion. Adjusted EBITDA is projected to range from $90 million to $115 million, while operating cash flow is expected to exceed $60 million.

The outlook suggests that cash generation will remain an important part of the investment case for SLQT. For a company with a relatively small equity-market value compared with its annual revenue, improvements in operating cash flow and balance-sheet strength could have an outsized effect on investor perceptions.

Investors will also be watching the healthcare-services division closely. Continued growth in SelectRx membership could gradually shift more of SelectQuote's business toward recurring healthcare revenue and reduce its dependence on the more seasonal economics of insurance-policy distribution.

For shareholders of SLQT, the latest results present a mixed picture: quarterly revenue and net income weakened compared with the prior year, while adjusted EBITDA improved and full-year cash generation strengthened substantially. Execution against the company's 2027 cash-flow and profitability targets will likely be an important factor in determining whether the stock can recover from its recent weakness.